行情

VSTM

VSTM

Verastem
NASDAQ

实时行情|Nasdaq Last Sale

1.900
-0.070
-3.55%
盘后: 1.900 0 0.00% 17:40 01/17 EST
开盘
1.980
昨收
1.970
最高
2.030
最低
1.850
成交量
137.15万
成交额
--
52周最高
3.685
52周最低
0.8300
市值
1.41亿
市盈率(TTM)
-1.1370
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VSTM 新闻

  • Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up
  • Zacks.01/09 14:00
  • 【美股盘前】欧美股指期指全线上涨,日本家庭对经济的信心降至五年来最低点
  • 每日经济新闻.01/09 10:52
  • VSTM, PIR, ADMS and ITCI among midday movers
  • Seeking Alpha - Article.01/08 17:44
  • TRXC, VSTM among premarket gainers
  • Seeking Alpha - Article.01/08 14:16

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

VSTM 简况

Verastem, Inc., is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. It is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma.
展开

Webull提供Verastem Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。